Compare Essex Property Trust, Inc. (ESS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novo Nordisk A/S — how do they compare? Essex Property Trust, Inc. trades at $271.57 (market cap $17.26B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 9.6× Essex Property Trust, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Novo Nordisk A/S for 116 Days on average.
| ESS | NVO | |
|---|---|---|
Market Cap | $17.26B | $165.31B |
Volume | 454,464 | 11,432,838 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $63.98 |
52-Week Low | $239.61 | $35.29 |
Typical Hold Time | 111 Days | 116 Days |
Enterprise Value | $23.86B | $179.56B |
Dividend Yield | 3.86% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $273.21, up 1.93% today, but technical indicators signal a bearish trend with resistance near $273. The company reported mixed quarterly earnings, beating in Q1 but missing in Q2 and Q4 2025, while maintaining strong profitability with a net margin of 21.48%. Recent news highlights strong Q2 2026 results and the resolution of litigation, improving the risk profile.
The outlook is cautiously optimistic with a consensus price target of $303.41, implying upside, but risks include earnings volatility and high debt levels. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid ongoing operational execution challenges in the real estate sector.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
